New hope for Hard-to-Treat kidney diseases in early trial
NCT ID NCT05267262
Summary
This study tested an experimental drug called R3R01 for people with two serious kidney diseases: Alport Syndrome and Focal Segmental Glomerulosclerosis (FSGS). The main goal was to see if the drug was safe and if it could reduce high levels of protein in the urine, a key sign of kidney damage. Forty-three patients aged 12 and older received the drug for 12 weeks, and researchers measured changes in their urine protein and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Los Angeles, California, 90022, United States
-
Investigative Site
Cary, North Carolina, 27511, United States
-
Investigative Site
Dallas, Texas, 75204, United States
-
Investigative site
Boca Raton, Florida, 33431, United States
-
Investigative site
Miami, Florida, 33136, United States
-
Investigative site
Riverview, Florida, 33578, United States
-
Investigative site
Atlanta, Georgia, 30322, United States
-
Investigative site
Boston, Massachusetts, 02111, United States
-
Investigative site
Ann Arbor, Michigan, 48109-5718, United States
-
Investigative site
Minneapolis, Minnesota, 55454, United States
-
Investigative site
Cleveland, Ohio, 44195, United States
-
Investigative site
Columbus, Ohio, 43235, United States
-
Investigative site
East Providence, Rhode Island, 02914, United States
-
Investigative site
Houston, Texas, 77054, United States
-
Investigative site
Brussels, 1200, Belgium
-
Investigative site
Liège, 4000, Belgium
-
Investigative site
Paris, 75015, France
-
Investigative site
Göttingen, 37075, Germany
-
Investigative site
Amsterdam, 1105AZ, Netherlands
-
Investigative site
Nijmegen, 6525 GA, Netherlands
-
Investigative site
Leicester, LE5 4PW, United Kingdom
-
Investigative site
Nottingham, NG5 1PB, United Kingdom
Conditions
Explore the condition pages connected to this study.